Related Experiment Videos
Sequential versus alternating chemotherapy for high grade non-Hodgkin's lymphomas: a randomized multicentre trial
H Köppler1, K H Pflüger, I Eschenbach
1Abt Hämatologie/Onkologie, Philipps-Universität, Marburg, Germany.
Hematological Oncology
|July 1, 1991
Summary
This phase III trial compared two chemotherapy regimens for high-grade non-Hodgkin's lymphomas. Both treatments showed similar complete response rates and survival outcomes, indicating comparable efficacy in previously untreated patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- High-grade non-Hodgkin's lymphomas (NHL) are aggressive cancers requiring effective treatment strategies.
- Optimizing chemotherapy regimens is crucial for improving patient outcomes in advanced-stage NHL.
- Previous treatment protocols have varied, necessitating comparative studies to identify superior therapeutic approaches.
Purpose of the Study:
- To compare the efficacy and safety of two distinct chemotherapy regimens in previously untreated patients with stage II-IV high-grade NHL.
- To evaluate complete response (CR) rates, relapse patterns, overall survival (OS), and disease-free survival (DFS) between the two treatment arms.
- To determine if a novel combination chemotherapy regimen offers advantages over a standard approach in this patient population.
Main Methods:
- A multicentre phase III clinical trial randomized 146 previously untreated patients with stage II-IV high-grade NHL.
- Treatment Arm A received four cycles of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone).
- Treatment Arm B received four cycles of alternating hCHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and IVEP (ifosfamide, vindesine, etoposide, prednisolone), followed by involved field irradiation for responders.
Main Results:
- A complete response (CR) was achieved in 86% of patients (87% in Arm A vs. 83% in Arm B).
- Over a median follow-up of 17 months, 30 patients relapsed (16 in Arm A, 14 in Arm B).
- Projected 40-month overall survival was 71% (Arm A) vs. 70% (Arm B), and disease-free survival was 68% (Arm A) vs. 59% (Arm B); differences were not statistically significant.
Conclusions:
- Both chemotherapy regimens demonstrated comparable efficacy in terms of complete response rates and survival outcomes for previously untreated high-grade NHL.
- The observed differences in disease-free survival between the arms did not reach statistical significance.
- Further investigation may be warranted to explore long-term outcomes and potential subtle differences between the treatment strategies.